With earlier diagnosis, the prognosis of those with liver cancer is greatly improved. Our VeraMarker™ metabolite profiling enables early, more accurate diagnosis.
We’re developing a colon cancer monitoring test using metabolite profiling that detects cancer recurrence earlier and more accurately than existing tests.
Matrix-Bio seeks to raise $750,000 to validate our Colon Cancer Monitoring test (CCM), the first of three tests for the more than $2 billion colon cancer testing market.
Matrix-Bio’s Dan Raftery co-authors peer-reviewed article on biomarkers for detecting liver cancer in Hepatitis C patients in Journal of Chromatography B.
Register for Updates
If you’re an investor or an oncologist interested in tracking Matrix-Bio’s progress, we invite your interest.
New molecular diagnostics such as DNA, RNA, and proteomics have not delivered the clinically actionable results envisioned. So why is metabolite profiling different?